Drugs / SJP-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07487909 | Sep → Nov 2025 | — | Sen-Jam Pharmaceutical | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-02-10 | Sen-Jam Pharmaceutical | Sen-Jam Pharmaceutical Engages Destum Partners to Source Strategic Partnerships for SJP-001 & SJP-002C sen-jam.com ↗ |
| 2025-01-14 | Sen-Jam Pharmaceutical | Sen-Jam Pharmaceutical Announces Ethics Approval in Australia for SJP-001 Clinical Trial Targeting Inflammation and Metabolic Health sen-jam.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SJP-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07487909 ↗ |
| Route | Oral | “SJP-001 (One oral capsule containing 60 mg fexofenadine HCl plus one oral capsule containing no more than 275 mg (preferably 220 mg) naproxen sodium)” NCT07487909 ↗ |